{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:56:27Z","timestamp":1772715387888,"version":"3.50.1"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Optimal care for children with HIV infection includes timely assessment of treatment failure. Using HIV viral load to define treatment failure remains a challenge in resource-limited settings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Children with HIV infection who were already on or starting first-line antiretroviral therapy were enrolled and followed over time. We examined clinical and immunologic predictors of virologic failure (VF), defined as consecutive viral load measurements &gt; 1000 copies\/mL (VF). Children were followed every 6 months with clinical assessments, immunologic assays and viral load testing until treatment failure or up to 18 months.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Of the 484 children with complete data, we observed a prevalence of 15% who had VF at enrollment, and 18 who developed VF over 10.5 person-years of follow-up for an incidence of 4.97 [95% CI: 3.04\u20137.70) per 100 person-years. Lower adherence, lower CD4 T-cell count, lower white blood cells count, lower platelets and a lower glomerular filtration rate were all associated with increased VF. However, in a multivariable analysis, renal function (estimated glomerular filtration rate &lt; 90\u2009mL\/min), odds ratio: 11.5 (95% CI: 1.5\u201363.7), and lower adherence, odds ratio: 3.9 (95% CI: 1.1\u201313.4), were the only factors associated with development of VF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>We identified a significant risk of VF in children with HIV infection in a prospective cohort study in southern Ethiopia and limited predictive value of clinical variables for VF. This provides further evidence that rapid and reliable viral load testing is needed to adequately address the HIV epidemic, along with implementation of adherence interventions in sub-Saharan Africa.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002898","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T16:00:55Z","timestamp":1600012855000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":14,"title":["Predictors of Virologic Failure Among a Cohort of HIV-infected Children in Southern Ethiopia"],"prefix":"10.1097","volume":"40","author":[{"given":"Birkneh Tilahun","family":"Tadesse","sequence":"first","affiliation":[{"name":"Department of Pediatrics, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron Alexander","family":"Foster","sequence":"additional","affiliation":[{"name":"School of Medicine"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emile","family":"Latour","sequence":"additional","affiliation":[{"name":"Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Youn","family":"Lim","sequence":"additional","affiliation":[{"name":"Biostatistics Shared Resource, Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Degu","family":"Jerene","sequence":"additional","affiliation":[{"name":"KNCV Tuberculosis Foundation, The Hague, the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Ruff","sequence":"additional","affiliation":[{"name":"Department of International Health, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eleni","family":"Aklillu","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,9,7]]},"reference":[{"key":"R3-20250615","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1177\/0956462413515639","article-title":"Population-level associations between antiretroviral therapy scale-up and all-cause mortality in South Africa.","volume":"25","author":"Larson","year":"2014","journal-title":"Int J STD AIDS"},{"key":"R6-20250615","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1097\/QAD.0b013e32830e4cd8","article-title":"Evaluation of the WHO criteria for antiretroviral treatment failure among adults in South Africa.","volume":"22","author":"Mee","year":"2008","journal-title":"AIDS"},{"key":"R7-20250615","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1758-2652-12-3","article-title":"Development and evaluation of a clinical algorithm to monitor patients on antiretrovirals in resource-limited settings using adherence, clinical and CD4 cell count criteria.","volume":"12","author":"Meya","year":"2009","journal-title":"J Int AIDS Soc"},{"key":"R8-20250615","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1186\/s12889-019-7078-5","article-title":"Clinical and immunological failure among HIV-positive adults taking first-line antiretroviral therapy in Dire Dawa, eastern Ethiopia.","volume":"19","author":"Lenjiso","year":"2019","journal-title":"BMC Public Health"},{"key":"R9-20250615","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1093\/cid\/cis433","article-title":"Prediction of treatment failure using 2010 World Health Organization Guidelines is associated with high misclassification rates and drug resistance among HIV-infected Cambodian children.","volume":"55","author":"Westley","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R10-20250615","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1097\/QAD.0b013e328349a414","article-title":"Development and validation of systems for rational use of viral load testing in adults receiving first-line ART in sub-Saharan Africa.","volume":"25","author":"Abouyannis","year":"2011","journal-title":"AIDS"},{"key":"R11-20250615","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S1473-3099(09)70136-7","article-title":"Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis.","volume":"9","author":"Gupta","year":"2009","journal-title":"Lancet Infect Dis"},{"key":"R12-20250615","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1097\/QAD.0b013e32832ac34e","article-title":"The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.","volume":"23","author":"Hosseinipour","year":"2009","journal-title":"AIDS"},{"key":"R13-20250615","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1097\/QAD.0b013e32830f97e2","article-title":"Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification.","volume":"22","author":"Petersen","year":"2008","journal-title":"AIDS"},{"key":"R14-20250615","doi-asserted-by":"crossref","first-page":"e013528","DOI":"10.1136\/bmjopen-2016-013528","article-title":"Cohort profile: improving treatment of HIV-infected Ethiopian children through better detection of treatment failure in southern Ethiopia.","volume":"7","author":"Tadesse","year":"2017","journal-title":"BMJ Open"},{"key":"R17-20250615","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline.","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"R20-20250615","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12981-018-0208-9","article-title":"Long-term virological outcome in children receiving first-line antiretroviral therapy.","volume":"15","author":"Chandrasekaran","year":"2018","journal-title":"AIDS Res Ther"},{"key":"R21-20250615","doi-asserted-by":"crossref","first-page":"e0200242","DOI":"10.1371\/journal.pone.0200242","article-title":"Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya.","volume":"13","author":"Kadima","year":"2018","journal-title":"PLoS One"},{"key":"R22-20250615","doi-asserted-by":"crossref","first-page":"e0200505","DOI":"10.1371\/journal.pone.0200505","article-title":"Baseline predictors of antiretroviral treatment failure and lost to follow up in a multicenter countrywide HIV-1 cohort study in Ethiopia.","volume":"13","author":"Telele","year":"2018","journal-title":"PLoS One"},{"key":"R23-20250615","doi-asserted-by":"crossref","first-page":"21140","DOI":"10.7448\/IAS.19.1.21140","article-title":"High levels of pre-treatment HIV drug resistance and treatment failure in Nigerian children.","volume":"19","author":"Boerma","year":"2016","journal-title":"J Int AIDS Soc"},{"key":"R24-20250615","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1093\/jac\/dky300","article-title":"Resistance profile and treatment outcomes in HIV-infected children at virological failure in Benin, West Africa.","volume":"73","author":"Fofana","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"R25-20250615","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v10020060","article-title":"High levels of dual-class drug resistance in HIV-infected children failing first-line antiretroviral therapy in Southern Ethiopia.","volume":"10","author":"Tadesse","year":"2018","journal-title":"Viruses"},{"key":"R26-20250615","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1093\/jac\/dkx188","article-title":"Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.","volume":"72","author":"Kityo","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"R27-20250615","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1093\/jac\/dkw218","article-title":"Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.","volume":"71","author":"Boender","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"R28-20250615","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/v11090877","article-title":"Prevalence and correlates of pre-treatment HIV drug resistance among HIV-infected children in Ethiopia.","volume":"11","author":"Tadesse","year":"2019","journal-title":"Viruses"},{"key":"R29-20250615","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12879-016-1968-2","article-title":"Prevalence and effect of pre-treatment drug resistance on the virological response to antiretroviral treatment initiated in HIV-infected children - a EuroCoord-CHAIN-EPPICC joint project.","volume":"16","author":"Ngo-Giang-Huong","year":"2016","journal-title":"BMC Infect Dis"},{"key":"R30-20250615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S1473-3099(11)70255-9","article-title":"Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study.","volume":"12","author":"Hamers","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"R31-20250615","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/23744235.2017.1371852","article-title":"A review of renal disease in children with HIV infection.","volume":"50","author":"Jindal","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"R32-20250615","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrneph.2015.9","article-title":"HIV-associated nephropathies: epidemiology, pathology, mechanisms and treatment.","volume":"11","author":"Rosenberg","year":"2015","journal-title":"Nat Rev Nephrol"},{"key":"R33-20250615","first-page":"e13","article-title":"Rebuttal: response to the comments by Buck et al. on our published article: Hepatic and renal toxicity and associated factors among HIV-infected children on antiretroviral therapy: a prospective cohort study; HIV Medicine (2019), 20, 147-156.","volume":"20","author":"Tadesse","year":"2019","journal-title":"HIV Med"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002898","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T16:05:56Z","timestamp":1750003556000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000002898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,7]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002898","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9,7]]}}}